126 related articles for article (PubMed ID: 36375380)
21. Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression.
Heinecke JL; Ridnour LA; Cheng RY; Switzer CH; Lizardo MM; Khanna C; Glynn SA; Hussain SP; Young HA; Ambs S; Wink DA
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6323-8. PubMed ID: 24733928
[TBL] [Abstract][Full Text] [Related]
22. SMAR1 promotes immune escape of Tri-negative Breast Cancer through a mechanism involving T-bet/PD-1 Axis.
Xiaohua W; Hongxia X; Rong D; Pingping W; Xing H; Yichao Z; Cheng C
Cell Mol Biol (Noisy-le-grand); 2018 Sep; 64(12):70-75. PubMed ID: 30301506
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors.
Baram T; Erlichman N; Dadiani M; Balint-Lahat N; Pavlovski A; Meshel T; Morzaev-Sulzbach D; Gal-Yam EN; Barshack I; Ben-Baruch A
Cells; 2021 Jun; 10(6):. PubMed ID: 34201054
[TBL] [Abstract][Full Text] [Related]
24. Cancer cell-derived exosomal miR-20a-5p inhibits CD8
Li W; Han G; Li F; Bu P; Hao Y; Huang L; Bai X
Cancer Sci; 2024 Feb; 115(2):347-356. PubMed ID: 38129137
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
Jovanovic IP; Pejnovic NN; Radosavljevic GD; Pantic JM; Milovanovic MZ; Arsenijevic NN; Lukic ML
Int J Cancer; 2014 Apr; 134(7):1669-82. PubMed ID: 24105680
[TBL] [Abstract][Full Text] [Related]
26. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
Gao M; Wang T; Ji L; Bai S; Tian L; Song H
Front Immunol; 2020; 11():366. PubMed ID: 32194569
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic targeting with DABIL-4 depletes myeloid suppressor cells in 4T1 triple-negative breast cancer model.
Parveen S; Siddharth S; Cheung LS; Kumar A; Shen J; Murphy JR; Sharma D; Bishai WR
Mol Oncol; 2021 May; 15(5):1330-1344. PubMed ID: 33682324
[TBL] [Abstract][Full Text] [Related]
28. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
29. LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer.
Carpenter KJ; Valfort AC; Steinauer N; Chatterjee A; Abuirqeba S; Majidi S; Sengupta M; Di Paolo RJ; Shornick LP; Zhang J; Flaveny CA
Sci Rep; 2019 Dec; 9(1):19530. PubMed ID: 31863071
[TBL] [Abstract][Full Text] [Related]
30. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
[TBL] [Abstract][Full Text] [Related]
31. Nitric oxide inhibits the accumulation of CD4+CD44hiTbet+CD69lo T cells in mycobacterial infection.
Pearl JE; Torrado E; Tighe M; Fountain JJ; Solache A; Strutt T; Swain S; Appelberg R; Cooper AM
Eur J Immunol; 2012 Dec; 42(12):3267-79. PubMed ID: 22890814
[TBL] [Abstract][Full Text] [Related]
32. Loss of the proprotein convertase Furin in T cells represses mammary tumorigenesis in oncogene-driven triple negative breast cancer.
He Z; Khatib AM; Creemers JWM
Cancer Lett; 2020 Aug; 484():40-49. PubMed ID: 32389711
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
34. Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.
O'Melia MJ; Manspeaker MP; Thomas SN
Cancer Immunol Immunother; 2021 Aug; 70(8):2179-2195. PubMed ID: 33459842
[TBL] [Abstract][Full Text] [Related]
35. The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma.
Kim SH; Roszik J; Cho SN; Ogata D; Milton DR; Peng W; Menter DG; Ekmekcioglu S; Grimm EA
Clin Cancer Res; 2019 Mar; 25(5):1650-1663. PubMed ID: 30538110
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
37. Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer.
Li G; Hu J; Cho C; Cui J; Li A; Ren P; Zhou J; Wei W; Zhang T; Liu X; Liu W
Cell Signal; 2023 Sep; 109():110729. PubMed ID: 37257766
[TBL] [Abstract][Full Text] [Related]
38. Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas.
Dawod B; Liu J; Gebremeskel S; Yan C; Sappong A; Johnston B; Hoskin DW; Marshall JS; Wang J
Sci Rep; 2020 Aug; 10(1):13343. PubMed ID: 32770025
[TBL] [Abstract][Full Text] [Related]
39. Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation.
Weinberg JB
Immunol Res; 2000; 22(2-3):319-41. PubMed ID: 11339365
[TBL] [Abstract][Full Text] [Related]
40. Intratumoral CD8
Virassamy B; Caramia F; Savas P; Sant S; Wang J; Christo SN; Byrne A; Clarke K; Brown E; Teo ZL; von Scheidt B; Freestone D; Gandolfo LC; Weber K; Teply-Szymanski J; Li R; Luen SJ; Denkert C; Loibl S; Lucas O; Swanton C; Speed TP; Darcy PK; Neeson PJ; Mackay LK; Loi S
Cancer Cell; 2023 Mar; 41(3):585-601.e8. PubMed ID: 36827978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
